Literature DB >> 25548493

Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors.

Mariko Furukori1, Koji Imai1, Hidenori Karasaki1, Kenji Watanabe1, Kensuke Oikawa1, Naoyuki Miyokawa1, Masahiko Taniguchi1, Hiroyuki Furukawa1.   

Abstract

AIM: To present our experiences in studying the clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors (NF-pNETs).
METHODS: The subjects included 9 patients with NF-pNETs who underwent pancreatectomy between April 1996 and September 2012. The surgical procedure, histopathological findings, and prognosis were assessed.
RESULTS: All tumors were incidentally detected by computed tomography. The median diameter was 10 mm (5-32 mm). One patient was diagnosed with von Hippel-Lindau disease, and the others were sporadic cases. For the histopathological findings, 7 patients were G1; 1 patient was G2; and 1 patient, whose tumor was 22 mm, had neuroendocrine carcinoma (NEC). One patient who had a tumor that was 32 mm had direct invasion to a regional lymph node and 1 patient with NEC, had regional lymph node metastases. Six of the 7 patients with sporadic NF-pNETs, excluding the patient with NEC, had tumors that were smaller than 10 mm. Tumors smaller than 10 mm showed no malignancy and lacked lymph node metastasis.
CONCLUSION: Sporadic NF-pNETs smaller than 10 mm tend to have less malignant potential. These findings suggest that lymphadenectomy may be omitted for small NF-pNETs after further investigation.

Entities:  

Keywords:  Lymphadenectomy; Nonfunctioning; Pancreatic neuroendocrine carcinoma; Pancreatic neuroendocrine tumor; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25548493      PMCID: PMC4273145          DOI: 10.3748/wjg.v20.i47.17949

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  [A case of nonfunctioning minute malignant pancreatic endocrine tumor, showing regional stenosis of the main pancreatic duct].

Authors:  R Higuchi; F Watanabe; Y Horio; M Kageoka; H Iwasaki; K Sugimoto; S Honda; K Koda
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2000-03

2.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Authors:  Francesco Panzuto; Silvia Nasoni; Massimo Falconi; Vito Domenico Corleto; Gabriele Capurso; Sara Cassetta; Michela Di Fonzo; Valentina Tornatore; Massimo Milione; Stefano Angeletti; Maria Sofia Cattaruzza; Vincenzo Ziparo; Cesare Bordi; Paolo Pederzoli; Gianfranco Delle Fave
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

4.  Endocrine pancreatic tumors: factors correlated with survival.

Authors:  P Tomassetti; D Campana; L Piscitelli; R Casadei; D Santini; F Nori; A M Morselli-Labate; R Pezzilli; R Corinaldesi
Journal:  Ann Oncol       Date:  2005-08-05       Impact factor: 32.976

5.  Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment.

Authors:  N P Jarufe; C Coldham; T Orug; A D Mayer; D F Mirza; J A C Buckels; S R Bramhall
Journal:  Dig Surg       Date:  2005-07-20       Impact factor: 2.588

6.  Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Authors:  Yassar M Hashim; Kathryn M Trinkaus; David C Linehan; Steven S Strasberg; Ryan C Fields; Dengfeng Cao; William G Hawkins
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

Review 7.  Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors.

Authors:  Henning Dralle; Sabine L Krohn; Wolfram Karges; Bernhard O Boehm; Michael Brauckhoff; Oliver Gimm
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

8.  A minute nonfunctioning islet cell tumor demonstrating malignant features.

Authors:  Naoki Ikenaga; Koji Yamaguchi; Hiroyuki Konomi; Kei Fujii; Atsushi Sugitani; Masao Tanaka
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

9.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  3 in total

1.  Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Authors:  Young Jin Yoo; Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Hogeun Kim; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

2.  Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Liang-Yu Lin; Yi-Chen Yeh; Chia-Huei Chu; Justin G S Won; Yi-Ming Shyr; Yee Chao; Chung-Pin Li; Shin-E Wang; Ming-Huang Chen
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

3.  Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.

Authors:  Shreya Mehta; Philip R de Reuver; Preetjote Gill; Juliana Andrici; Lisa D'Urso; Anubhav Mittal; Nick Pavlakis; Stephen Clarke; Jaswinder S Samra; Anthony J Gill
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.